De genética

Como hemos hecho en trimestres anteriores presentamos los resultados económicos para los dos CAR.T  autorizados y además de los datos nos parece interesante traer aquí lo que dicen las empresas sobre sus productos. En el informe de los resultados que presenta Novartis para el Q1 2019 referentes a Kymriah  dice: Kymriah (USD 45 million) strong demand continued and sales increased driven by new treatment sites in the EU, additional progress with reimbursement, providing coverage for at least one indication in 14 countries, increased manufacturing capacity and widened commercial specifications in the EU . (pag 4) Kymriah received Japan approval for the treatment of relapsed or refractory (r/r) DLBCL and (r/r) pediatric ALL. With this approval, Kymriah is the first and only CAR-T cell therapy to receive regulatory approval in Asia; and follows the successful technical transfer at the Foundation for Biomedical Research and Innovation at Kobe for the clinical manufactur...